Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 48

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 48
---
 patients more efficiently; vii. secured rights to develop a CD73 inhibitor(uliledlimab) in China, from VJ Pharma, a company spun out from I-Mab; and viii. entered into an exclusive licensing agreement (i) with RadioMedix to develop radiopharmaceuticals for PET imaging and targeted alpha therapy (TAT) to respond to unmet medical needs in cancer, and (ii) with Orano Med to develop lead-212 (212Pb) radioligand therapies (RLTs) for cancer. 3) Accelerate efficiency In October 2023, we announced new Strategic Costs Initiatives. We are improving our cost structure, launching efficiency initiatives across our Biopharma business to free operational resources to support R&D investment and unlock value-creation opportunities. This includes prioritizing our investments in R&D and modernizing our approach to commercial delivery. To transform the practice of medicine, we are developing and deploying AI-powered solutions across all business units at all levels of Sanofi, not only to increase automation and efficiency, but also to fundamentally change the way we work and think. We are investing in computational tools and AI to become the leading digital healthcare platform for employees, patients and providers. AI and data science are already supporting our teams in areas such as accelerating drug discovery, improving clinical trial design, and streamlining the manufacture and supply of drugs and vaccines. We are driving a company-wide culture shift that embeds digital DNA into the fabric of our organization. O ur R&D teams are already accelerating their work: our Target Discovery engines have delivered seven novel drug targets in just one year, while our mRNA modelling solution has cut mRNA design time in half. Our Manufacturing & Supply (M&S) teams are saving time on time-consuming tasks and spending more time taking action based on data insights. By assessing data trends and identifying production outliers, we help our teams optimize the use of raw materials and resources as they manufacture and

| 20 | SANOFIFORM 20-F2024 |

| PART I                             |
| ITEM 4. Information on the Company |

distribute life-changing therapies to patients around the globe. Our Portfolio Strategy teams are using AI to leverage data such as internal clinical-trial and commercial data, as well as external information like competitor news flow, to predict value drivers such as R&D costs, trial enrollment, and a program’s probability of success. In 2024, we achieved key AI milestones across the business: • in partnership with Aily Labs, we deployed the